Literature DB >> 34889375

Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Daniel R Richardson1, Amy E DeZern2.   

Abstract

This is a focused clinical vignette and review of the literature in MDS to discuss the application of molecular sequencing for risk stratification in MDS. The authors utilize an exemplar patient case and explain the advantages and disadvantages, based on available data, of routine use of this testing for MDS patients.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34889375      PMCID： PMC8791107          DOI： 10.1182/hematology.2021000320

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  30 in total

Review 1.  NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Authors:  Fabio Forghieri; Ambra Paolini; Monica Morselli; Sara Bigliardi; Goretta Bonacorsi; Giovanna Leonardi; Valeria Coluccio; Monica Maccaferri; Valeria Fantuzzi; Laura Faglioni; Elisabetta Colaci; Francesco Soci; Vincenzo Nasillo; Andrea Messerotti; Laura Arletti; Valeria Pioli; Patrizia Zucchini; Chiara Quadrelli; Giorgia Corradini; Francesca Giacobbi; Daniela Vallerini; Giovanni Riva; Patrizia Barozzi; Ivana Lagreca; Roberto Marasca; Franco Narni; Cristina Mecucci; Emanuela Ottaviani; Giovanni Martinelli; Brunangelo Falini; Mario Luppi; Leonardo Potenza
Journal:  Leuk Lymphoma       Date:  2015-05-12

Review 2.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

3.  FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.

Authors:  Ashish Bains; Rajyalakshmi Luthra; L Jeffrey Medeiros; Zhuang Zuo
Journal:  Am J Clin Pathol       Date:  2011-01       Impact factor: 2.493

4.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett A Caughey; Omar Abdel-Wahab; David P Steensma; Naomi Galili; Azra Raza; Hagop Kantarjian; Ross L Levine; Donna Neuberg; Guillermo Garcia-Manero; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

5.  FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Naval Daver; Paolo Strati; Elias Jabbour; Tapan Kadia; Raja Luthra; Sa Wang; Keyur Patel; Farhad Ravandi; Jorge Cortes; Xiao Qin Dong; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2012-10-31       Impact factor: 10.047

6.  Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Authors:  Ayalew Tefferi; Naseema Gangat; Mythri Mudireddy; Terra L Lasho; Christy Finke; Kebede H Begna; Michelle A Elliott; Aref Al-Kali; Mark R Litzow; C Christopher Hook; Alexandra P Wolanskyj; William J Hogan; Mrinal M Patnaik; Animesh Pardanani; Darci L Zblewski; Rong He; David Viswanatha; Curtis A Hanson; Rhett P Ketterling; Jih-Luh Tang; Wen-Chien Chou; Chien-Chin Lin; Cheng-Hong Tsai; Hwei-Fang Tien; Hsin-An Hou
Journal:  Mayo Clin Proc       Date:  2018-06-14       Impact factor: 7.616

Review 7.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

Review 8.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Authors:  Luca Malcovati; Kristen Stevenson; Elli Papaemmanuil; Donna Neuberg; Rafael Bejar; Jacqueline Boultwood; David T Bowen; Peter J Campbell; Benjamin L Ebert; Pierre Fenaux; Torsten Haferlach; Michael Heuser; Joop H Jansen; Rami S Komrokji; Jaroslaw P Maciejewski; Matthew J Walter; Michaela Fontenay; Guillermo Garcia-Manero; Timothy A Graubert; Aly Karsan; Manja Meggendorfer; Andrea Pellagatti; David A Sallman; Michael R Savona; Mikkael A Sekeres; David P Steensma; Sudhir Tauro; Felicitas Thol; Paresh Vyas; Arjan A Van de Loosdrecht; Detlef Haase; Heinz Tüchler; Peter L Greenberg; Seishi Ogawa; Eva Hellstrom-Lindberg; Mario Cazzola
Journal:  Blood       Date:  2020-07-09       Impact factor: 25.476

9.  Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

Authors:  David A Sallman; Amy E DeZern; Guillermo Garcia-Manero; David P Steensma; Gail J Roboz; Mikkael A Sekeres; Thomas Cluzeau; Kendra L Sweet; Amy McLemore; Kathy L McGraw; John Puskas; Ling Zhang; Jiqiang Yao; Qianxing Mo; Lisa Nardelli; Najla H Al Ali; Eric Padron; Greg Korbel; Eyal C Attar; Hagop M Kantarjian; Jeffrey E Lancet; Pierre Fenaux; Alan F List; Rami S Komrokji
Journal:  J Clin Oncol       Date:  2021-01-15       Impact factor: 44.544

10.  Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.

Authors:  Matteo Bersanelli; Erica Travaglino; Manja Meggendorfer; Tommaso Matteuzzi; Claudia Sala; Ettore Mosca; Chiara Chiereghin; Noemi Di Nanni; Matteo Gnocchi; Matteo Zampini; Marianna Rossi; Giulia Maggioni; Alberto Termanini; Emanuele Angelucci; Massimo Bernardi; Lorenza Borin; Benedetto Bruno; Francesca Bonifazi; Valeria Santini; Andrea Bacigalupo; Maria Teresa Voso; Esther Oliva; Marta Riva; Marta Ubezio; Lucio Morabito; Alessia Campagna; Claudia Saitta; Victor Savevski; Enrico Giampieri; Daniel Remondini; Francesco Passamonti; Fabio Ciceri; Niccolò Bolli; Alessandro Rambaldi; Wolfgang Kern; Shahram Kordasti; Francesc Sole; Laura Palomo; Guillermo Sanz; Armando Santoro; Uwe Platzbecker; Pierre Fenaux; Luciano Milanesi; Torsten Haferlach; Gastone Castellani; Matteo G Della Porta
Journal:  J Clin Oncol       Date:  2021-02-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.